What makes a bacterial oral vaccine a strong inducer of high-affinity IgA responses?

Antibodies

Volumn 4, Issue 4, 2015, Pages 295-313

  Moor, Kathrin ^a   Slack, Emma ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Adjuvant; Gut associated lymphoid tissue; High affinity intestinal IgA; Live attenuation; Oral vaccine; Vaccination strategies

Indexed keywords

ADENYLATE CYCLASE; ARABINOSE; BACTERIAL VACCINE; CD103 ANTIGEN; DECTIN 1; GALACTOSE; GUANINE; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LIVE VACCINE; NANOPARTICLE; PIMELIC ACID DERIVATIVE; PURINE NUCLEOTIDE; RETINOIC ACID; TOLL LIKE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTATION; AUXOTROPHY; BACTERIAL COLONIZATION; BACTERIAL METABOLISM; BACTERIAL VIRULENCE; BIOSYNTHESIS; CHEMICAL MUTAGENESIS; DNA RECOMBINATION; GENETIC VARIABILITY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INTESTINE LYMPHATIC TISSUE; INTRACELLULAR SIGNALING; MICROFLORA; MUCOSAL IMMUNITY; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; VACCINATION;

EID: 84962619212     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib4040295     Document Type: Review

References (107)

1. Macpherson, A.J.; Uhr, T. Compartmentalization of the mucosal immune responses to commensal intestinal bacteria. Ann. NY Acad. Sci. 2004, 1029, 36–43.
2. Martinoli, C.; Chiavelli, A.; Rescigno, M. Entry route of Salmonella typhimurium directs the type of induced immune response. Immunity 2007, 27, 975–984.
3. Date, K.A.; Bentsi-Enchill, A.; Marks, F.; Fox, K. Typhoid fever vaccination strategies. Vaccine 2015, 33 (Suppl. 3), C55–C61.
4. Kabir, S. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clin. Vaccine Immunol. 2014, 21, 1195–1205.
5. Peterson, D.A.; Cardona, R.A. Specificity of the adaptive immune response to the gut microbiota. Adv. Immunol. 2010, 107, 71–107.
6. Stecher, B.; Robbiani, R.; Walker, A.W.; Westendorf, A.M.; Barthel, M.; Kremer, M.; Chaffron, S.; Macpherson, A.J.; Buer, J.; Parkhill, J.; et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol. 2007, 5, 2177–2189.
7. Lupp, C.; Robertson, M.L.; Wickham, M.E.; Sekirov, I.; Champion, O.L.; Gaynor, E.C.; Finlay, B.B. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2, 119–129.
8. Sztein, M.B.; Salerno-Goncalves, R.; McArthur, M.A. Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forward. Front. Immunol. 2014, 5, 516.
9. Bishop, A.L.; Camilli, A. Vibrio cholerae: Lessons for mucosal vaccine design. Expert Rev. Vaccines 2011, 10, 79–94.
10. Franco, M.A.; Angel, J.; Greenberg, H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24, 2718–2731.
11. Viret, J.F.; Dietrich, G.; Favre, D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 2004, 22, 2457–2469.
12. Ryan, E.T.; Calderwood, S.B.; Qadri, F. Live attenuated oral cholera vaccines. Expert Rev. Vaccines 2006, 5, 483–494.
13. Hoiseth, S.K.; Stocker, B.A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981, 291, 238–239.
14. Eisenstein, T.K.; Killar, L.M.; Stocker, B.A.; Sultzer, B.M. Cellular immunity induced by avirulent Salmonella in LPS-defective C3H/HeJ mice. J. Immunol. 1984, 133, 958–961.
15. Killar, L.M.; Eisenstein, T.K. Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: Studies with an aromatic-dependent live S. typhimurium strain as a vaccine. Infect. Immun. 1985, 47, 605–612.
16. Harrison, J.A.; Villarreal-Ramos, B.; Mastroeni, P.; Demarco de Hormaeche, R.; Hormaeche, C.E. Correlates of protection induced by live Aro- Salmonella typhimurium vaccines in the murine typhoid model. Immunology 1997, 90, 618–625.
17. Hormaeche, C.E.; Mastroeni, P.; Harrison, J.A.; Demarco de Hormaeche, R.; Svenson, S.; Stocker, B.A.D. Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)- dependent and only partially determined by the main LPS O antigen. Vaccine 1996, 14, 251–259.
18. Chatfield, S.N.; Strahan, K.; Pickard, D.; Charles, I.G.; Hormaeche, C.E.; Dougan, G. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb. Pathog. 1992, 12, 145–151.
19. Lowe, D.C.; Savidge, T.C.; Pickard, D.; Eckmann, L.; Kagnoff, M.F.; Dougan, G.; Chatfield, S.N. Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA. Infect. Immun. 1999, 67, 700–707.
20. Tacket, C.O.; Sztein, M.B.; Losonsky, G.A.; Wasserman, S.S.; Nataro, J.P.; Edelman, R.; Pickard, D.; Dougan, G.; Chatfield, S.N.; Levine, M.M. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 1997, 65,452–456.
21. Simon, R.; Tennant, S.M.; Galen, J.E.; Levine, M.M. Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: Revisiting the role of host innate susceptibility and routes of challenge. Vaccine 2011, 29, 5094–5106.
22. Curtiss, R., 3rd; Kelly, S.M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 1987, 55, 3035–3043.
23. Coe, N.E.; Wood, R.L. The effect of exposure to a delta cya/delta crp mutant of Salmonella typhimurium on the subsequent colonization of swine by the wild-type parent strain. Vet. Microbiol. 1992, 31, 207–220.
24. Hassan, J.O.; Curtiss, R., 3rd. Control of colonization by virulent Salmonella typhimurium by oral immunization of chickens with avirulent delta cya delta crp S. typhimurium. Res. Microbiol. 1990, 141, 839–850.
25. Hassan, J.O.; Curtiss, R., 3rd. Effect of vaccination of hens with an avirulent strain of Salmonella typhimurium on immunity of progeny challenged with wild-Type Salmonella strains. Infect. Immun. 1996, 64, 938–944.
26. Galan, J.E.; Curtiss, R., 3rd. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb. Pathog. 1989, 6, 433–443.
27. Hohmann, E.L.; Oletta, C.A.; Miller, S.I. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1996, 14, 19–24.
28. Matsui, H.; Isshiki, Y.; Eguchi, M.; Ogawa, Y.; Shimoji, Y. Evaluation of the live vaccine efficacy of virulence plasmid-cured, and phoP- or aroA-deficient Salmonella enterica serovar Typhimurium in mice. J. Vet. Med. Sci. 2015, 77, 181–186.
29. Matsui, H.; Suzuki, M.; Isshiki, Y.; Kodama, C.; Eguchi, M.; Kikuchi, Y.; Motokawa, K.; Takaya, A.; Tomoyasu, T.; Yamamoto, T. Oral immunization with ATP-dependent protease-deficient mutants protects mice against subsequent oral challenge with virulent Salmonella enterica serovar typhimurium. Infect. Immun. 2003, 71, 30–39.
30. Dilts, D.A.; Riesenfeld-Örn, I.; Fulginiti, J.P.; Ekwall, E.; Granert, C.; Nonenmacher, J.; Brey, R.N.; Cryz, S.J.; Karlsson, K.; Bergman, K.; et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 2000, 18, 1473–1484.
31. Hone, D.M.; Tacket, C.O.; Harris, A.M.; Kay, B.; Losonsky, G.; Levine, M.M. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Invest. 992, 90, 412–420.
32. Tacket, C.O.; Hone, D.M.; Curtiss, R., 3rd; Kelly, S.M.; Losonsky, G.; Guers, L.; Harris, A.M.; Edelman, R.; Levine, M.M. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect. Immun. 1992, 60, 536–541.
33. Casanova, J.L.; Jouanguy, E.; Lamhamedi, S.; Blanche, S.; Fischer, A. Immunological conditions of children with BCG disseminated infection. Lancet 1995, 346, 581.
34. Hesseling, A.C.; Rabie, H.; Marais, B.J.; Manders, M.; Lips, M.; Schaaf, H.S.; Gie, R.P.; Cotton, M.F.; van Helden, P.D.; Warren, R.M.; et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 2006, 42, 548–558.
35. Felmy, B.; Songhet, P.; Slack, E.M.C.; Müller, A.J.; Kremer, M.; Van Maele, L.; Cayet, D.; Heikenwalder, M.; Sirard, J.-C.; Hardt, W.D. NADPH oxidase deficient mice develop colitis and bacteremia upon infection with normally avirulent, TTSS-1- and TTSS-2-deficient Salmonella Typhimurium. PLoS ONE 2013, 8, e77204.
36. Vishwakarma, V.; Pati, N.B.; Chandel, H.S.; Sahoo, S.S.; Saha, B.; Suar, M. Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice. PLoS ONE 2012, 7, e52043.
37. Periaswamy, B.; Maier, L.; Vishwakarma, V.; Slack, E.; Kremer, M.; Andrews-Polymenis, H.L.; McClelland, M.; Grant, A.J.; Suar, M.; Hardt, W.-D. Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. PLoS ONE 2012, 7, e45433.
38. Pati, N.B.; Vishwakarma, V.; Selvaraj, S.K.; Dash, S.; Saha, B.; Singh, N.; Suar, M. Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection. BMC Microbiol. 2013, 13, 236.
39. Vishwakarma, V.; Pati, N.B.; Ray, S.; Das, S.; Suar, M. TTSS2-deficient hha mutant of Salmonella Typhimurium exhibits significant systemic attenuation in immunocompromised hosts. Virulence 2014, 5, 311–320.
40. Kaiser, P.; Diard, M.; Stecher, B.; Hardt, W.-D. The streptomycin mouse model for Salmonella diarrhea: functional analysis of the microbiota, the pathogen's virulence factors, and the host's mucosal immune response. Immunol. Rev. 2012, 245, 56–83.
41. Ackermann, M.; Stecher, B.; Freed, N.E.; Songhet, P.; Hardt, W.-D.; Doebeli, M. Self- destructive cooperation mediated by phenotypic noise. Nature 2008, 454, 987–990.
42. Diard, M.; Garcia, V.; Maier, L.; Remus-Emsermann, M.N.P.; Regoes, R.R.; Ackermann, M.; Hardt, W.-D. Stabilization of cooperative virulence by the expression of an avirulent phenotype. Nature 2013, 494, 353–356.
43. Stecher, B.; Hardt, W.D. Mechanisms controlling pathogen colonization of the gut. Curr. Opin. Microbiol. 2011, 14, 82–91.
44. Germanier, R.; Fuer, E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 1975, 131, 553–558.
45. Xu, D.; Cisarb, J.O.; Polyc, F.; Yangb, J.; Albanesea, J.; Dharmasenaa, M.; Waia, T.; Guerryc, P.; Kopeckoa, D.J. Genome Sequence of Salmonella enterica Serovar Typhi Oral Vaccine Strain Ty21a. Genome Announc. 2013, 1, e00650-13.
46. Kaiser, P.; Regoes, R.R.; Dolowschiak, T.; Wotzka, S.Y.; Lengefeld, J.; Slack, E.; Grant, A.J.; Ackermann, M.; Hardt, W.-D. Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment. PLoS Biol. 2014, 12, e1001793.
47. Grant, A.J.; Morgan, F.J.E.; McKinley, T.J.; Foster, G.L.; Maskell, D.J.; Mastroeni, P. Attenuated Salmonella Typhimurium lacking the pathogenicity island-2 type 3 secretion system grow to high bacterial numbers inside phagocytes in mice. PLoS Pathog. 2012, 8, e1003070.
48. Endt, K.; Stecher, B.; Chaffron, S.; Slack, E.; Tchitchek, N.; Benecke, A.; Van Maele, L.; Sirard, J.-C.; Mueller, A.J.; Heikenwalder, M.; et al. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog. 2010, 6, e1001097.
49. Curtiss, R., 3rd; Wanda, S.-Y.; Gunn, B.M.; Zhang, X.; Tinge, S.A.; Ananthnarayan, V.; Mo, H.; Wang, S.; Kong, W. Salmonella enterica serovar typhimurium strains with regulated delayed attenuation in vivo. Infect. Immun. 2009, 77, 1071–1082.
50. Kong, W.; Wanda, S.-Y.; Gunn, B.M.; Zhang, X.; Tinge, S.A.; Ananthnarayan, V.; Mo, H.; Wang, S.; Kong, W. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc. Natl. Acad. Sci. USA 2008, 105, 9361–9366.
51. Ng, K.M.; Ferreyra, J.A.; Higginbottom, S.K.; Lynch, J.B.; Kashyap, P.C.; Gopinath, S.; Naidu, N.; Choudhury, B.; Weimer, B.C.; Monack, D.M.; et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013, 502, 96–99.
52. Wang, S.; Curtiss, R., 3rd. Development of Vaccines Using Live Vectors. Vaccines (Basel) 2014, 2, 49–88.
53. Hapfelmeier, S.; Lawson, M.A.E.; Slack, E.; Kirundi, J.K.; Stoel, M.; Heikenwalder, M.; Cahenzli, J.; Velykoredko, Y.; Balmer, M.L.; Endt, K.; et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science 2010, 328, 1705–1709.
54. Nagano, K.; Taguchi, K.; Tokoro, S.; Tatsuno, I.; Mori, H. Adhesion of enterohemorrhagic Escherichia coli O157:H7 to the intestinal epithelia is essential for inducing secretory IgA antibody production in the intestine of mice. Biol. Pharm. Bull. 2014, 37, 409–416.
55. Garside, P.; Millington, O.; Smith, K.M. The anatomy of mucosal immune responses. Ann. NY Acad. Sci. 2004, 1029, 9–15.
56. Langridge, W.; Denes, B.; Fodor, I. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases. Curr. Opin. Investig. Drugs 2010, 11, 919–928.
57. Svennerholm, A.M.; Holmgren, J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect. Immun. 1976, 13, 735–740.
58. Black, R.E.; Levine, M.M.; Clements, M.L.; Young, C.R.; Svennerholm, A.M.; Holmgren, J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 1987, 55, 1116–1120.
59. Barthel, M.; Hapfelmeier, S.; Quintanilla-Martínez, L.; Kremer, M.; Rohde, M.; Hogardt, M.; Pfeffer, K.; Rüssmann, H.; Hardt, W.-D. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect. Immun. 2003, 71, 2839–2858.
60. Hapfelmeier, S.; Hardt, W.D. A mouse model for S. typhimurium-induced enterocolitis. Trends Microbiol. 2005, 13, 497–503.
61. Hapfelmeier, S.; Ehrbar, K.; Stecher, B.; Barthel, M.; Kremer, M.; Hardt, W.-D. Role of the Salmonella pathogenicity island 1 effector proteins SipA, SopB, SopE, and SopE2 in Salmonella enterica subspecies 1 serovar Typhimurium colitis in streptomycin-pretreated mice. Infect. Immun. 2004, 72, 795–809.
62. Neutra, M.R.; Mantis, N.J.; Kraehenbuhl, J.P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat. Immunol. 2001, 2, 1004–1009.
63. Mabbott, N.A.; Donaldson, D.S.; Ohno, H.; Williams, I.R.; Mahajan, A. Microfold (M) cells: Important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013, 6, 666–677.
64. Howe, S.E.; Lickteig, D.J.; Plunkett, K.N.; Ryerse, J.S.; Konjufca, V. The Uptake of Soluble and Particulate Antigens by Epithelial Cells in the Mouse Small Intestine. PLoS ONE 2014, 9, doi:10.1371/journal.pone.0086656.
65. Strindelius, L.; Degling Wikingsson, L.; Sjoholm, I. Extracellular antigens from Salmonella enteritidis induce effective immune response in mice after oral vaccination. Infect. Immun. 2002, 70, 1434–1442.
66. Strindelius, L.; Filler, M.; Sjoholm, I. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. Vaccine 2004, 22, 3797–3808.
67. Strindelius, L.; Folkesson, A.; Normark, S.; Sjöholm, I. Immunogenic properties of the Salmonella atypical fimbriae in BALB/c mice. Vaccine 2004, 22, 1448–1456.
68. Weiner, H.L.; da Cunha, A.P.; Quintana, F.; Wu, H. Oral tolerance. Immunol. Rev. 2011, 241, 241–259.
69. Macpherson, A.J.; Uhr, T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004, 303, 1662–1665.
70. Howe, S.E.; Konjufca, V.H. Per-oral immunization with antigen-conjugated nanoparticles followed by sub-cutaneous boosting immunization induces long-lasting mucosal and systemic antibody responses in mice. PLoS ONE 2015, 10, e0118067.
71. De Smet, R.; Demoor, T.; Verschuere, S.; Dullaers, M.; Ostroff, G.R.; Leclercq, G.; Allais, L.; Pilette, C.; Dierendonck, M.; De Geest, B.G.; et al. beta-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. J. Control. Release 2013, 172, 671–678.
72. Rochereau, N.; Drocourt, D.; Perouzel, E.; Pavot, V.; Redelinghuys, P.; Brown, G.D.; Tiraby, G.; Roblin, X.; Verrier, B.; Genin, C.; et al. Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells. PLoS Biol. 2013, 11, e1001658.
73. Vyas, S.P.; Gupta, P.N. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 2007, 6, 401–418.
74. Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989, 54 (Pt. 1), 1–13.
75. Glenn, G.M.; Francis, D.H.; Danielsen, E.M. Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect. Immun. 2009, 77, 5206–5215.
76. Fan, E.; O’Neal, C.J.; Mitchell, D.D.; Robien, M.A.; Zhang, Z.; Pickens, J.C.; Tan, X.-J.; Korotkov, K.; Roach, C.; Krumm, B.; et al. Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin. Int. J. Med. Microbiol. 2004, 294, 217–223.
77. Lycke, N.; Bemark, M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. 2010, 3, 556–566.
78. Iwata, M.; Hirakiyama, A.; Eshima, Y.; Kagechika, H.; Kato, C.; Song, S.-Y. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004, 21, 527–538.
79. Benson, M.J.; Pino-Lagos, K.; Rosemblatt, M.; Noelle, R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 2007, 204, 1765–1774.
80. Chen, Q.; Mosovsky, K.L.; Ross, A.C. Retinoic acid and alpha-galactosylceramide regulate the expression of costimulatory receptors and transcription factors responsible for B cell activation and differentiation. Immunobiology 2013, 218, 1477–1487.
81. Mora, J.R.; Pino-Lagos, K.; Rosemblatt, M.; Noelle, R.J. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006, 314, 1157–1160.
82. Pantazi, E.; Iwata, M.; Eksteen, B.; Song, S.-Y.; Junt, T.; Senman, B.; Otipoby, K.L.; Yokota, A.; Takeuchi, H.; Ricciardi-Castagnoli, P.; et al. Cutting Edge: Retinoic Acid Signaling in B Cells Is Essential for Oral Immunization and Microflora Composition. J. Immunol. 2015, 314, 1157–1160.
83. Hammerschmidt, S.I.; Friedrichsen, M.; Boelter, J.; Lyszkiewicz, M.; Kremmer, E.; Pabst, O.; Förster, R. Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice. J. Clin. Invest. 2011, 121, 3051–3061.
84. Tan, X.; Sande, J.L.; Pufnock, J.S.; Blattman, J.N.; Greenberg, P.D. Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge. J. Virol. 2011, 85, 8316–8327.
85. Milpied, P.J.; McHeyzer-Williams, M.G. High-affinity IgA needs TH17 cell functional plasticity. Nat. Immunol. 2013, 14, 313–315.
86. Grassly, N.C.; Jafari, H.; Bahl, S.; Durrani, S.; Wenger, J.; Sutter, R.W.; Aylward, R.B. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J. Infect. Dis. 2009, 200, 794–801.
87. Jiang, V.; Jafari, H.; Bahl, S.; Durrani, S.; Wenger, J.; Sutter, R.W.; Aylward, R.B. Performance of rotavirus vaccines in developed and developing countries. Hum. Vaccin 2010, 6, 532–542.
88. Lopman, B.A.; Pitzer, V.E.; Sarkar, R.; Gladstone, B.; Patel, M.; Glasser, J.; Gambhir, M.; Atchison, C.; Grenfell, B.; Edmunds, W.J.; et al. Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. PLoS ONE 2012, 7, e41720.
89. Levine, M.M. Immunogenicity and efficacy of oral vaccines in developing countries: Lessons from a live cholera vaccine. BMC Biol. 2010, 8, 129.
90. Mora, J.R.; Iwata, M.; von Andrian, U.H. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat. Rev. Immunol. 2008, 8, 685–698.
91. Kaufman, D.R.; De Calisto, J.; Simmons, N.L.; Cruz, A.N.; Villablanca, E.J.; Mora, J.R.; Barouch, D.H. Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity. J. Immunol. 2011, 187, 1877–1883.
92. Ibs, K.H.; Rink, L. Zinc-altered immune function. J. Nutr. 2003, 133 (Suppl. 1), 1452S-1456S.
93. Korpe, P.S.; Petri, W.A., Jr. Environmental enteropathy: Critical implications of a poorly understood condition. Trends Mol. Med. 2012, 18, 328–336.
94. Keusch, G.T.; Denno, D.M.; Black, R.E.; Duggan, C.; Guerrant, R.L.; Lavery, J.V.; Nataro, J.P.; Rosenberg, I.H.; Ryan, E.T.; Tarr, P.I.; et al. Environmental enteric dysfunction: Pathogenesis, diagnosis, and clinical consequences. Clin. Infect. Dis. 2014, 59 (Suppl. 4), S207–S212.
95. Majumder, P.P.; Sarkar-Roy, N.; Staats, H.; Ramamurthy, T.; Maiti, S.; Chowdhury, G.; Whisnant, C.C.; Narayanasamy, K.; Wagener, D.K. Genomic correlates of variability in immune response to an oral cholera vaccine. Eur. J. Hum. Genet. 2013, 21, 1000–1006.
96. Stecher, B.; Chaffron, S.; Käppeli, R.; Hapfelmeier, S.; Freedrich, S.; Weber, T.C.; Kirundi, J.; Suar, M.; McCoy, K.D.; von Mering, C.; et al. Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. PLoS Pathog. 2010, 6, e1000711.
97. Moon, C.; Baldridge, M.T.; Wallace, M.A.; Burnham, C.-A.D.; Virgin, H.W.; Stappenbeck, T.S. Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation. Nature 2015, 521, 90–93.
98. Endt, K.; Maier, L.; Käppeli, R.; Barthel, M.; Misselwitz, B.; Kremer, M.; Hardt, W.-D. Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not. Antimicrob. Agents Chemother. 2012, 56, 2295–2304.
99. Uchiyama, R.; Chassaing, B.; Zhang, B.; Gewirtz, A.T. Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J. Infect. Dis. 2014, 210, 171–182.
100. Praharaj, I.; John, S.M.; Bandyopadhyay, R.; Kang, G. Probiotics, antibiotics and the immune responses to vaccines. Philos. T. R. Soc. B 2015, 370, doi:10.1098/rstb.2014.0144.
101. Lindner, C.; Wahl, B.; Föhse, L.; Suerbaum, S.; Macpherson, A.J.; Prinz, I.; Pabst, O. Age, microbiota, and T cells shape diverse individual IgA repertoires in the intestine. J. Exp. Med. 2012, 209, 365–377.
102. Kole, A.; Maloy, K.J. Control of intestinal inflammation by interleukin-10. Curr. Top. Microbiol. Immunol. 2014, 380, 19–38.
103. Bollrath, J.; Powrie, F.M. Controlling the frontier: regulatory T-cells and intestinal homeostasis. Semin. Immunol. 2013, 25, 352–357.
104. Geuking, M.B.; Cahenzli, J.; Lawson, M.A.E.; Ng, D.C.K.; Slack, E.; Hapfelmeier, S.; McCoy, K.D.; Macpherson, A.J. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011, 34, 794–806.
105. Lindner, C.; Thomsen, I.; Wahl, B.; Ugur, M.; Sethi, M.K.; Friedrichsen, M.; Smoczek, A.; Ott, S.; Baumann, U.; Suerbaum, S.; et al. Diversification of memory B cells drives the continuous adaptation of secretory antibodies to gut microbiota. Nat. Immunol. 2015, 16, 880–888.
106. Akram, A.; Inman, R.D. Immunodominance: A pivotal principle in host response to viral infections. Clin. Immunol. 2012, 143, 99–115.
107. Buchbinder, S.P.; Mehrotra, D.V.; Duerr, A.; Fitzgerald, D.W.; Mogg, R.; Li, D.; Gilbert, P.B.; Lama, J.R.; Marmor, M.; del Rio, C.; et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372, 1881–1893.